Search results for "lignan"
showing 3 items of 613 documents
Survival trends for primary liver cancer, 1995–2009: analysis of individual data for 578,740 patients from 187 population-based registries in 36 coun…
2019
CONCORD Working Group Members: Africa—Algeria: S Bouzbid (Registre du Cancer d’Annaba); M Hamdi-Chérif*, Z Zaidi (Registre du Cancer de Sétif); Gambia: R Swaminathan (National Cancer Registry); Lesotho: SH Nortje (Children’s Haematology Oncology Clinics - Lesotho); Libya: MM El Mistiri (Benghazi Cancer Registry); Mali: S Bayo, B Malle (Kankou Moussa University); Mauritius: SS Manraj, R Sewpaul-Sungkur (Mauritius National Cancer Registry); Nigeria: A Fabowale, OJ Ogunbiyi* (Ibadan Cancer Registry); South Africa: D Bradshaw, NIM Somdyala (Eastern Cape Province Cancer Registry); DC Stefan (Umtata University); Tunisia: L Jaidane, M Mokni (Registre du Cancer du Centre Tunisien). America (Central…
Comparative histological and immunohistochemical study of ameloblastomas and ameloblastic carcinomas
2017
Background This study aimed to compare the histological and immunohistochemical characteristics of ameloblastomas (AM) and ameloblastic carcinomas (AC). Material and Methods Fifteen cases of AM and 9 AC were submitted to hematoxilin and eosin (H&E) and immunohistochemical analysis with the following antibodies: cytokeratins 5,7,8,14 and 19, Ki-67, p53, p63 and the cellular adhesion molecules CD138 (Syndecan-1), E-cadherin and β-catenin. The mean score of the expression of Ki-67 and p53 labelling index (LIs) were compared between the groups using the t test. A value of p<0.05 was considered to be statistically significant. Results All cases were positive for CKs 5, 14 and 19, but negative fo…
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus
2019
Background. Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available. Methods. Given this, an expert panel endorsed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on Thrombosis and Haemostasis was set up to produce a formal consensus, according to the RAND method, in order to issue clinical recommendations about the platelet (PLT) cut-off for safe administration of low molecular weight heparin (LMWH) in thrombocytopenic (PLT <100×…